Prevalence of Mupirocin Resistance in Staphylococcus pseudintermedius
Stacey Marie Godbeer, Randi M. Gold, Sara D. Lawhon
Abstract
Open-access reader
Stacey Marie Godbeer, Randi M. Gold, Sara D. Lawhon
Abstract
Open-access reader
In the United States, veterinary use of mupirocin is primarily limited to the treatment of canine pyoderma caused by methicillin-resistant Staphylococcus pseudintermedius (MRSP). In this study, only 1 of 581 S. pseudintermedius isolates tested was resistant to mupirocin and carried the high-level mupirocin resistance gene, ileS2, on a plasmid.
OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In the United States, veterinary use of mupirocin is primarily limited to the treatment of canine pyoderma caused by methicillin-resistant Staphylococcus pseudintermedius (MRSP). In this study, only 1 of 581 S. pseudintermedius isolates tested was resistant to mupirocin and carried the high-level mupirocin resistance gene, ileS2, on a plasmid.
Key concepts: Staphylococcus pseudintermedius, Mupirocin, Pyoderma, Microbiology, Medicine, Staphylococcus, Staphylococcus aureus, Staphylococcal infections